Orchid Pharma Ltd (ORCHPHARMA) share price, results, shareholding

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	198.76	220.59	217.10	244.41	222.70	217.34	237.48	263.19	193.52	207.27	368.33	304.17
Expenses	175.46	185.21	188.19	211.92	192.36	190.97	209.49	268.84	194.99	205.71	338.17	290.17
Operating Profit	23.30	35.38	28.91	32.49	30.34	26.37	27.99	-5.65	-1.47	1.56	30.16	14.00
OPM %	11.72%	16.04%	13.32%	13.29%	13.62%	12.13%	11.79%	-2.15%	-0.76%	0.75%	8.19%	4.60%
Other Income	8.36	7.62	13.36	7.57	7.52	8.49	3.90	11.57	10.77	-1.50	7.55	1.83
Interest	3.80	3.54	3.47	3.50	3.33	3.80	3.92	2.28	3.73	3.18	1.96	2.23
Depreciation	7.84	9.27	8.42	8.44	8.63	8.61	8.87	10.53	8.90	9.03	10.90	10.95
Profit before tax	20.02	30.19	30.38	28.12	25.90	22.45	19.10	-6.89	-3.33	-12.15	24.85	2.65
Tax %	0.00%	0.00%	-10.27%	-0.53%	0.00%	0.00%	-0.21%	0.00%	0.00%	0.00%	0.00%	2.64%
Net Profit	19.80	29.43	32.96	29.35	27.24	20.78	22.29	-5.69	-5.72	-12.61	25.84	3.22
EPS in Rs	3.90	5.80	6.50	5.79	5.37	4.10	4.39	-1.12	-1.13	-2.49	5.09	0.63

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	873	797	683	600	484	450	560	666	819	1,398	1,233	1,073
Expenses	703	794	659	612	515	421	505	581	708	1,247	1,185	1,029
Operating Profit	171	3	24	-12	-31	29	55	84	111	151	48	44
OPM %	20%	0.4%	3.6%	-2.0%	-6%	7%	10%	13%	14%	11%	3.9%	4.1%
Other Income	-28	-59	20	218	24	15	67	52	31	26	15	19
Interest	294	347	310	7	6	52	33	33	17	13	9	11
Depreciation	145	141	133	130	118	109	87	55	33	42	43	40
Profit before tax	-296	-544	-399	69	-131	-117	2	48	92	122	10	12
Tax %	-6%	-9%	-12%	0%	0%	0%	0%	0%	-3%	-8%	-2%
Net Profit	-279	-495	-353	69	-131	-117	-2	46	92	135	10	11
EPS in Rs	-31.37	-55.69	-39.65	7.80	-32.11	-28.55	-0.48	11.35	18.17	26.63	1.96	2.10
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

	10 Years	5 Years	3 Years	TTM	1 Year	Last Year
Compounded Sales Growth	4%	22%	23%	14%
Compounded Profit Growth	8%	17%	53%	-72%
Stock Price CAGR	39%	19%	24%		43%
Return on Equity	%	5%	7%			1%

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	85	89	89	89	89	41	41	41	41	51	15	15
Reserves	244	-40	-556	-881	-793	725	612	607	648	1,119	1,494	1,504
Borrowings	3,211	3,215	3,106	3,202	3,230	566	453	268	331	135	154	307
Other Liabilities	521	598	616	715	551	128	132	195	205	249	414	432
Total Liabilities	4,061	3,862	3,256	3,125	3,077	1,460	1,237	1,111	1,225	1,554	2,077	2,258
Fixed Assets	1,795	1,637	1,497	1,386	1,256	858	670	584	573	620	708	692
CWIP	282	280	288	272	278	26	7	10	46	31	81	414
Investments	1	1	1	1	0	0	15	45	44	46	60	67
Other Assets	1,984	1,944	1,470	1,467	1,542	576	544	472	561	857	1,229	1,086
Total Assets	4,061	3,862	3,256	3,125	3,077	1,460	1,237	1,111	1,225	1,554	2,077	2,258

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-369	212	401	9	12	81	24	92	18	126	51	126
Cash from Investing Activity	1,334	-1	-176	-28	45	167	67	113	-31	-312	-36	-277
Cash from Financing Activity	-597	-286	-465	33	-0	-250	-165	-217	31	167	2	137
Net Cash Flow	367	-76	-240	15	57	-2	-74	-11	18	-19	17	-14
Free Cash Flow	965	211	392	3	5	77	23	238	-8	61	-102	-255
CFO/OP	-102%	124%	13,628%	67%	-138%	-226%	63%	173%	22%	113%	44%	259%

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	54	130	75	64	73	51	110	111	118	87	92	113
Inventory Days	118	220	196	202	214	254	244	201	217	199	187	161
Days Payable	146	341	402	374	381	182	176	195	165	173	137	150
Cash Conversion Cycle	26	9	-130	-108	-94	123	179	117	170	113	142	124
Working Capital Days	-49	-168	-500	-876	-1,158	166	302	97	54	118	101	105
ROCE %	1%	1%	-4%	-4%	-5%	-6%	-5%	-2%	5%	9%	9%	2%

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	72.40%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%
FIIs	8.08%	4.14%	1.96%	1.42%	1.94%	2.53%	2.69%	1.39%	1.56%	1.17%	0.87%	0.80%
DIIs	12.46%	14.51%	17.73%	18.93%	18.30%	19.00%	20.10%	19.43%	19.04%	19.38%	20.24%	20.75%
Public	7.05%	11.52%	10.47%	9.82%	9.94%	8.63%	7.37%	9.34%	9.57%	9.61%	9.04%	8.62%
No. of Shareholders	29,197	36,931	36,720	34,695	36,363	34,158	34,303	39,827	38,155	35,709	35,118	33,433

Fundamentals

Market Cap₹ 6,078 Cr.

Current Price₹ 1,015

Stock P/E337

Book Value₹ 300

ROCE1.86 %

ROE1.49 %

Dividend Yield0.00 %

Face Value₹ 10.0

Compounded Sales Growth (TTM)14%

Compounded Profit Growth (TTM)-72%

Consolidated figures.

Valuation

Market capRs 5,929 Cr

Enterprise valueRs 6,152 Cr

P/E (TTM)552.53x

Price to book3.90x

Price to sales5.52x

EV / EBITDA97.80x

EV / EBIT266.08x

EV / sales5.73x

Price to cash flow47.19x

Earnings yield0.18%

P/E, 3-year average46.80x

P/B, 3-year average1.93x

P/E, 5-year average43.54x

P/B, 5-year average1.97x

Profitability

Operating margin (excl. other income)3.87%

Operating margin (incl. other income)5.11%

EBITDA margin5.86%

Pre-tax margin1.12%

Net profit margin1.00%

Net margin, latest quarter1.06%

ROE0.66%

ROCE1.13%

ROA0.46%

ROE, 3-year average6.89%

ROCE, 3-year average6.52%

ROA, 3-year average4.84%

ROE, 5-year average5.46%

ROCE, 5-year average6.29%

ROA, 5-year average3.67%

ROIC (approx.)1.35%

Tax rate-1.82%

Other income / net worth1.01%

Growth

Sales growth (latest year)-11.79%

Profit growth (latest year)-92.63%

Sales CAGR, 3 years22.79%

Sales CAGR, 5 years22.33%

Profit CAGR, 3 years-40.09%

Sales growth QoQ-17.42%

Profit growth QoQ-87.54%

Sales growth YoY (latest quarter)15.57%

Per share

EPS (TTM)Rs 1.79

EPS (latest year)Rs 6.51

EPS (latest quarter)Rs 0.54

EPS, 3-year averageRs 37.66

EPS, 5-year averageRs 24.77

Book value per shareRs 253.77

Sales per shareRs 179.22

Cash flow per shareRs 20.98

Free cash flow per shareRs -42.58

Efficiency

Asset turnover0.55x

Fixed asset turnover1.78x

Inventory turnover2.64x

Inventory days138 days

Debtor days113 days

Debtors turnover3.23x

Creditor days150 days

Cash conversion cycle124 days

Working capital days105 days

Leverage

Total debtRs 307 Cr

Cash and bankRs 84 Cr

Net debtRs 223 Cr

Debt to equity0.20x

Net debt / EBITDA3.55x

Interest coverage2.08x

Current ratio (filing 2026-03-31)1.89x

Quick ratio (filing 2026-03-31)1.13x

Trade payables (filing 2026-03-31)Rs 347 Cr

Owners' fund to total sources67.29%

Debt to assets13.57%

Cash flow

Cash from Operating Activity (latest year)Rs 126 Cr

Cash from Investing Activity (latest year)Rs -277 Cr

Cash from Financing Activity (latest year)Rs 137 Cr

Net Cash Flow (latest year)Rs -14 Cr

Free cash flow (latest year)Rs -255 Cr

FCFE (approx.: FCF + change in debt)Rs -102 Cr

Cash from ops / profit, 5 years1.47x

Sales to cash flow9.81x

Statement figures

Net sales (TTM)Rs 1,073 Cr

Net sales (latest year)Rs 1,233 Cr

Sales (latest quarter)Rs 304 Cr

Operating profit excl. other income (latest year)Rs 48 Cr

Operating profit (latest quarter)Rs 14 Cr

Other income (TTM)Rs 19 Cr

EBITDA (TTM)Rs 63 Cr

PBDT (TTM)Rs 52 Cr

Profit before tax (TTM)Rs 12 Cr

Tax (latest year)Rs -0 Cr

Net profit (TTM)Rs 11 Cr

Net profit (latest year)Rs 10 Cr

Net profit (latest quarter)Rs 3 Cr

Depreciation (TTM)Rs 40 Cr

Depreciation (latest quarter)Rs 11 Cr

Interest (TTM)Rs 11 Cr

Cost of goods sold (latest year)Rs 982 Cr

Total expenditure (latest year)Rs 1,185 Cr

Total income (latest year)Rs 1,248 Cr

Share capitalRs 15 Cr

ReservesRs 1,504 Cr

Shareholders' fundsRs 1,520 Cr

Total assetsRs 2,258 Cr

Net blockRs 692 Cr

Capital work in progressRs 414 Cr

InvestmentsRs 67 Cr

ReceivablesRs 381 Cr

InventoryRs 372 Cr

Other liabilitiesRs 432 Cr

Shares outstanding (crore)5.99

Ownership

Promoter holding69.84% (+0.00 in a year)

Computed by MarketFriction from the consolidated statements. Returns use average balances.

P/B 3.90 is at the 56th percentile (median 3.77).

Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.

Period	ORCHPHARMA	Nifty 50	Difference
1 week	-9.7%	-2.8%	-6.9 pts
1 month	+4.4%	-6.8%	+11.2 pts
3 months	+3.5%	-7.6%	+11.1 pts
6 months	+105.2%	+0.4%	+104.8 pts
1 year	+34.2%	-9.9%	+44.1 pts
2 years	-29.3%	-13.6%	-15.7 pts
3 years	+86.2%	+14.2%	+72.0 pts
5 years	+131.4%	+27.9%	+103.6 pts

28 mutual fund schemes hold about ₹982 Cr. Over three months 2 bought more and 19 sold (share counts, price move removed).

Fund	Weight	Est. Cr	3m shares
Quant Small Cap Fund	0.95%	337	-11%
UTI Value Fund	1.22%	117	-13%
Invesco India Contra Fund	0.47%	96	-7%
Kotak Multi Asset Allocation Fund	0.60%	92	-10%
UTI Small Cap Fund	0.91%	48	+66%
Kotak Special Opportunities Fund	2.73%	46	-8%
Invesco India Smallcap Fund	0.28%	44	-18%
Bandhan Small Cap Fund	0.13%	43	-20%
Kotak Consumption Fund	1.60%	28	-5%
Kotak MNC Fund	1.09%	25	-9%
Kotak Multi Cap Fund	0.08%	25	-12%
Tata India Innovation Fund	1.04%	14	-1%
PGIM India Small Cap Fund	0.76%	14	-11%
Kotak Healthcare Fund	1.64%	11	-8%
UTI Healthcare Fund	0.68%	10	-13%
Bandhan Multi Cap Fund	0.32%	10	-37%
Bandhan Multi Asset Allocation Fund	0.16%	6	-57%
UTI Conservative Hybrid Fund(M	0.30%	5	-18%
WOC Pharma and Healthcare Fund	0.41%	4	+34%
Bandhan Healthcare Fund	1.08%	4	-37%
Kotak Balanced Advantage Fund	0.01%	2	-3%
Invesco India Equity Savings Fund	0.37%	1	+1%
Invesco India Equity Savings Fund	0.37%	1	+1%
PGIM India Healthcare Fund	0.80%	1	-20%
Bandhan Balanced Advantage Fund	0.01%	0	-3%

Red flags

F-score 4 of 8

explain	Debt up, profit down Borrowings up 99% while net profit fell in 2026
look	Profit leans on other income Other income was 147% of pre-tax profit in 2026
look	Regulator order or action Regulator order or action 2026-06-11: Orchid Pharma Limited has informed the Exchange about Action(s) taken or orders passed
look	Auditor change Auditor change 2026-05-25: Orchid Pharma Limited has informed the Exchange regarding Change in Auditors of the company.

Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026

Sales ₹304 Cr +15.6% vs Jun 2025. Net profit ₹3 Cr +156.6%.

Activity

Compare

Company	Mcap (Cr)	P/E	ROCE
Sun Pharmaceutical Industries Ltd	447,476	35.4	20.5 %
Divis Laboratories Ltd	250,363	84.0	22.0 %
Torrent Pharmaceuticals Ltd	186,152	83.4	15.2 %
Zydus Lifesciences Ltd	119,750	24.6	21.1 %
Cipla Ltd	111,430	31.1	15.5 %
Laurus Labs Ltd	106,928	97.8	17.8 %
Mankind Pharma Ltd	105,120	49.3	13.5 %
Dr Reddys Laboratories Ltd	104,494	32.4	13.0 %
Aurobindo Pharma Ltd	97,682	25.8	12.9 %
Lupin Ltd	93,840	15.8	29.9 %
Glenmark Pharmaceuticals Ltd	68,905	22.1	39.8 %
Alkem Laboratories Ltd	62,772	27.6	21.2 %
Biocon Ltd	61,439	84.5	3.61 %
Abbott India Ltd	57,949	35.9	44.8 %
Gland Pharma Ltd	49,333	43.1	15.1 %

No bulk or block deals on record.

Ex-date	Action	Factor
2023-08-02	Annual General Meeting
2022-12-22	Extra Ordinary General Meeting
2022-07-06	Annual General Meeting
2021-08-04	Annual General Meeting
2021-06-18	Extra Ordinary General Meeting
2020-12-21	Annual General Meeting

Date	Type	What it says
2026-10-01	Shareholder meeting	Voting results.
2026-09-29	Shareholder meeting	Proceedings of the 33rd Annual General Meeting held on September 29, 2026
2026-09-23	Updates	Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation.
2026-09-22	Updates	Intimation under Regulation 30 of SEBI ( Listing obligation and Disclosure Requirement) Regulations, 2015.
2026-09-21	Updates	Investor Roadshow Scheduled to be held in Mumbai.
2026-09-08	Updates	Business Responsibility and Sustainability Report for FY 2025-26.
2026-09-07	Shareholder meeting	Notice of Annual General Meeting to be held on September 29, 2026
2026-09-03	Change in Management	Appointment of cost auditor and change in designation of a Director.
2026-09-03	Board meeting outcome	Outcome of Board Meeting held on September 03, 2026.
2026-08-24	Concall / analyst meet	Transcript
2026-08-21	Concall / analyst meet	Link of Recording
2026-08-20	Concall / analyst meet	Presentation
2026-08-17	Concall / analyst meet	Schedule of meet
2026-08-14	Monitoring Agency Report	Monitoring Agency Report for the Ouarter-I of Financial Year 2026-27, ended on June 30, 2026- Orchid Pharma Limited ("the Company")
2026-08-14	Board meeting outcome	Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-08-14	Board meeting outcome	Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-01	Allotment	Allotment of 44586052 securities pursuant to Scheme of Arrangement/Amalgamation at its meeting held on August 01, 2026
2026-08-01	Board meeting outcome	Outcome of Board Meeting held on August 01, 2026.
2026-07-25	Updates	Intimation regarding investor roadshow .
2026-07-10	Record Date	Record date for the purpose of Merger/HiveOff is 23-Jul-2026.
2026-07-10	Amendment to AOA/MOA	The Amendment to AOA/MOA of the company.
2026-07-10	Board meeting outcome	Outcome of the Board Meeting: Noting the effect of Scheme of Amalgamation
2026-07-10	Updates	Update related to the Scheme of Amalgamation of Dhanuka Laboratories Limited ("Amalgamating Company") with Orchid Pharma Limited ("Amalgamated Company...
2026-07-07	Press Release	A press release dated 0 ,
2026-06-12	General Updates	General Updates

Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.

No short selling reported to NSE in our files.

Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.

Order date	Forum	Case
2020-11-12	NCLT	The Resolution Professional (Orchid Pharma Ltd) Vs Kailasam Raghavendra Rao
2020-11-12	NCLT	(Orchid Pharma Ltd) Vs Kalilasam Raghavendra Rao & 3 Others

Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.

Close to Close price movement greater than 75perc in previous 6 monthsHigh low price variation greater than 100perc in previous 6 monthsScrip PE is greater than 50 (4 trailing quarters)